 "Image via Shutterstock")
Divi's Laboratories has informed the stock exchanges that the US drug regulator has issued a warning letter for its unit-II at Visakhapatnam, Andhra Pradesh.
"We will respond to this warning letter with a detailed plan within the stipulated time," the company said in a statement on Saturday, without disclosing the details of the warning letter.
Divi's Laboratories, along with external consultants and subject matter experts, is working to address the concerns of the US Food and Drug Administration (USFDA) and is making all efforts to fully meet the compliance requirements, it said.
The US FDA had earlier
"We will respond to this warning letter with a detailed plan within the stipulated time," the company said in a statement on Saturday, without disclosing the details of the warning letter.
Divi's Laboratories, along with external consultants and subject matter experts, is working to address the concerns of the US Food and Drug Administration (USFDA) and is making all efforts to fully meet the compliance requirements, it said.
The US FDA had earlier
